Therapeutic drug monitoring of aminoglycosides: Is achieving PK/PD targets associated with better clinical outcomes in patients with cystic fibrosis?
Abstract
Background Aminoglycosides are widely used in dual antipseudomonal therapy for acute pulmonary exacerbations in cystic fibrosis (CF). Due to altered pharmacokinetics in CF, achieving recommended pharmacokinetic/pharmacodynamic (PK/PD) targets is challenging and the impact of target attainment on clinical outcomes remains unclear. Objectives To evaluate whether currently recommended aminoglycoside dosing regimens in CF achieve PK/PD targets in clinical practice, and whether target attainment correlates with clinical improvements in CF patients. Design/methods A two-year, single-center cohort study was conducted in adult CF patients receiving aminoglycoside during acute exacerbation. Aminoglycoside levels were obtained to estimate PK parameters. Clinical symptoms and pulmonary function were assessed at admission (baseline) and discharge. Results Fourteen treatment courses were analyzed among nine patients. Amikacin (n=10, mean dose 30.9 ± 2 mg/kg), or gentamicin (n=4, mean dose 10.5 ± 0.7 mg/kg) were administered. The target C max :MIC ratio of 8-10 was achieved in 50% of amikacin courses and none of the gentamicin courses. Most patients improved clinically, evident by symptoms’ resolution and increased ppFEV 1 . Target attainment was associated with a numerically greater ppFEV 1 improvement, though not statistically significant (P=0.29). Conclusions The pre-defined PK/PD target was attained in less than half of the cases treated, underscoring the need for optimized dosing strategies. Nonetheless, clinical improvement occurred regardless of target attainment. This highlights the need of larger randomized controlled studies to define the relationship between aminoglycoside PK/PD target achievement and clinical outcomes among CF patients.
Related
- Circulating Biomarkers with Artificial Intelligence for Clinical Risk Assessment and Therapeutic Monitoring: Evidence, Limitations, and Translation
- Dermoscopic Monitoring of Therapeutic Regression in Actinic Lichen Planus: A Practical Illustration of Inflammoscopy in Clinical Care.
- Consensus Guidance for Beta‐Lactam Antibiotic Dose Individualization in Acutely Ill Patients: Endorsed by the American College of Clinical Pharmacy, European Society of Clinical Microbiology and Infectious Diseases, European Society of Clinical Microbiology and Infectious Diseases PK/PD of Anti‐Infectives Study Group, Infectious Diseases Society of America, International Association of Therapeutic Drug Monitoring and Clinical Toxicology, Society of Critical Care Medicine, and the Society of Infectious Diseases Pharmacists
- Integrating the gut microbiome into therapeutic drug monitoring and model-informed precision dosing: a clinical pharmacy perspective
- Pharmacokinetic/Pharmacodynamic Optimization and Therapeutic Drug Monitoring of Beta-Lactam Antibiotics in Abdominal Sepsis: Current Evidence, Challenges, and Clinical Perspectives—A Narrative Review
BibTeX
@article{elajez2026therapeutic,
title = {{Therapeutic drug monitoring of aminoglycosides: Is achieving PK/PD targets associated with better clinical outcomes in patients with cystic fibrosis?}},
author = {Reem Elajez and Dana Bakdach and Mousa Hussein and Anam Elarabi and Abdullah Mohammad and Aisha Al-Adab and Mona Al-Langawi and Merlin Thomas},
journal = {Therapeutic Advances in Infectious Disease},
year = {2026},
month = oct,
doi = {10.1177/20499361261503133},
url = {https://doi.org/10.1177/20499361261503133},
note = {CC BY},
}
RIS
TY - JOUR
TI - Therapeutic drug monitoring of aminoglycosides: Is achieving PK/PD targets associated with better clinical outcomes in patients with cystic fibrosis?
AU - Reem Elajez
AU - Dana Bakdach
AU - Mousa Hussein
AU - Anam Elarabi
AU - Abdullah Mohammad
AU - Aisha Al-Adab
AU - Mona Al-Langawi
AU - Merlin Thomas
PY - 2026
DA - 2026/10/28
JO - Therapeutic Advances in Infectious Disease
DO - 10.1177/20499361261503133
UR - https://doi.org/10.1177/20499361261503133
AB - Background Aminoglycosides are widely used in dual antipseudomonal therapy for acute pulmonary exacerbations in cystic fibrosis (CF). Due to altered pharmacokinetics in CF, achieving recommended pharmacokinetic/pharmacodynamic (PK/PD) targets is challenging and the impact of target attainment on clinical outcomes remains unclear. Objectives To evaluate whether currently recommended aminoglycoside dosing regimens in CF achieve PK/PD targets in clinical practice, and whether target attainment correlates with clinical improvements in CF patients. Design/methods A two-year, single-center cohort study was conducted in adult CF patients receiving aminoglycoside during acute exacerbation. Aminoglycoside levels were obtained to estimate PK parameters. Clinical symptoms and pulmonary function were assessed at admission (baseline) and discharge. Results Fourteen treatment courses were analyzed among nine patients. Amikacin (n=10, mean dose 30.9 ± 2 mg/kg), or gentamicin (n=4, mean dose 10.5 ± 0.7 mg/kg) were administered. The target C max :MIC ratio of 8-10 was achieved in 50% of amikacin courses and none of the gentamicin courses. Most patients improved clinically, evident by symptoms’ resolution and increased ppFEV 1 . Target attainment was associated with a numerically greater ppFEV 1 improvement, though not statistically significant (P=0.29). Conclusions The pre-defined PK/PD target was attained in less than half of the cases treated, underscoring the need for optimized dosing strategies. Nonetheless, clinical improvement occurred regardless of target attainment. This highlights the need of larger randomized controlled studies to define the relationship between aminoglycoside PK/PD target achievement and clinical outcomes among CF patients.
SN - 2049-937X
SN - 2049-9361
ER -